Among patients with type 2 diabetes (T2D), the risk of acute kidney injury (AKI) after sodium-glucose co-transporter 2 inhibitor (SGLT2i) treatment is higher in men, older adults, and those with low body mass index (BMI), chronic heart failure, and concomitant diuretic use, a study has found.
Depression appears to be prevalent among type 2 diabetes (T2D) patients, especially among those who are younger, female, with lower socioeconomic status, and are experiencing hypoglycaemic episodes, among others, according to data from the DEPDIAB study. Moreover, frequent episodes of hypoglycaemia heighten the risk of suicidal ideation among patients with depression.
The dual SGLT1/2* inhibitor sotagliflozin significantly lowers the risk of the composite outcome of cardiovascular (CV) deaths, hospitalizations for heart failure (HHF), and urgent visits for heart failure in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), regardless of albuminuria status, according to the SCORED trial presented at ADA 2021.
In patients with type 2 diabetes (T2D), once-weekly doses of the dual glucose-dependent insulinotropic polypeptide–GLP-1* receptor agonist tirzepatide for 40 weeks resulted in superior HbA1c reductions compared with the GLP-1 receptor agonist semaglutide, according to results from the phase III SURPASS-2** trial presented at ADA 2021.
Rheumatoid arthritis (RA) patients who also have diabetes mellitus (DM) are at risk of greater worsening or less improvement in functional status, reveals a study, suggesting that additional interventions may be needed to optimize treatment and management of other comorbidities.
Treatment with pioglitazone, even at low doses, helps improve indices of nonalcoholic fatty liver disease (NAFLD) such as liver steatosis, inflammation, and systemic and adipose tissue insulin resistance in patients with type 2 diabetes, according to a study.
A three-component lifestyle intervention (LSI) programme* was effective in improving the metabolic health and weight of reproductive-aged women with polycystic ovarian syndrome (PCOS), according to data presented at ESHRE 2021.
The extended-release fixed-dose combination of naltrexone and bupropion (NB) appears to induce weight loss in obese or overweight patients with type 2 diabetes mellitus (T2DM) receiving treatment with dipeptidyl peptidase 4 inhibitors (DPP-4is) or glucagon-like peptide-1 receptor agonists (GLP1-RAs), according to a post-hoc analysis of the LIGHT trial.